- Report
- October 2023
- 146 Pages
Global
From €3407EUR$3,528USD£2,915GBP
€4008EUR$4,150USD£3,430GBP
- Report
- March 2024
- 186 Pages
Global
From €3259EUR$3,374USD£2,789GBP
€3621EUR$3,749USD£3,099GBP
- Report
- April 2024
- 88 Pages
Global
From €5409EUR$5,600USD£4,628GBP
- Report
- January 2024
- 200 Pages
Global
From €4829EUR$5,000USD£4,132GBP
- Report
- January 2024
- 150 Pages
Global
From €4684EUR$4,850USD£4,009GBP
- Report
- May 2021
- 174 Pages
Global
From €1328EUR$1,375USD£1,136GBP
€2656EUR$2,750USD£2,273GBP
- Report
- December 2022
- 180 Pages
Global
From €5747EUR$5,950USD£4,918GBP
- Report
- August 2023
- 74 Pages
Egypt
From €3380EUR$3,500USD£2,893GBP
- Report
- April 2022
- 181 Pages
Global
From €3076EUR$3,185USD£2,632GBP
€4394EUR$4,550USD£3,761GBP
- Report
- November 2020
- 96 Pages
Global
From €3863EUR$4,000USD£3,306GBP
- Report
- November 2023
- 84 Pages
Global
From €3500EUR$3,882USD£3,100GBP
The Liver Cancer Diagnostics market is a subset of the larger Diagnostics industry. It is focused on the development and commercialization of tests and technologies used to detect and diagnose liver cancer. These tests can include imaging techniques such as ultrasound, computed tomography (CT) scans, and magnetic resonance imaging (MRI). Additionally, blood tests, biopsies, and other laboratory tests may be used to diagnose liver cancer.
The Liver Cancer Diagnostics market is highly competitive, with a range of companies offering products and services. These include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Becton Dickinson, and Hologic. Other companies in the market include Agilent Technologies, Bio-Rad Laboratories, and Cepheid. Show Less Read more
